Advertisement

Behandlung der schizophrenen Negativsymptomatik mit Dopamin-Autorezeptor-Agonisten: Erste Erfahrungen mit Roxindol

  • H. Wetzel
  • A. Hillert
  • G. Gründer

Zusammenfassung

Nach psychopathologischen und neuroradiologisch-neuropathologischen Gesichtspunkten und im Hinblick auf Unterschiede in Therapie und Verlauf wurde von Crow (1980; 1985) und — mit etwas anderer Akzentuierung — von Andreasen u. Olsen (1982) eine Unterteilung schizophrener Syndrome in einen positiven und negativen Subtyp vorgeschlagen. Positivsymptome wie Wahn oder Halluzinationen wurden mit einer funktioneilen Überaktivität mesolimbischer dopaminerger Neuronensysteme, Negativsymptome wie Affektverflachung, gedankliche und sprachliche Verarmung, Antriebsstörungen und soziale Rückzugstendenzen hingegen mit strukturmorphologischen Hirnveränderungen in Zusammenhang gebracht. Während Positivsymptome in der Regel recht gut auf Neuroleptika — die alle mehr oder weniger stark Dopaminrezeptoren blockieren — ansprechen, ist deren Wirkung bei Negativsymptomatik häufig wenig zufriedenstellend (Johnstone et al. 1976; Weinberger et al. 1980), wenngleich diese Einschätzung nicht unwidersprochen geblieben ist (Goldberg 1985; Meltzer et al. 1986).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Andreasen NC, Olsen SA (1982) Negative vs positive schizophrenia: definition and validation. Arch Gen Psychiatry 39: 789–794.PubMedCrossRefGoogle Scholar
  2. Arnt J, Hyttel J (1984) Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats. J Neural Transm 60: 205–223.PubMedCrossRefGoogle Scholar
  3. Carpenter WT, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11: 440–452.PubMedGoogle Scholar
  4. Clark D, Hjorth S, Carlsson A (1985) Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm 62: 1–52.PubMedCrossRefGoogle Scholar
  5. Corsini GU, Del Zompo M, Manconi S, Cianchetti C, Mangoni A, Gessa GL (1977) Sedative, hypnotic and antipsychotic effects of low doses of apomorphine in man. Adv Biochem Psychopharmacol 16: 645–648.PubMedGoogle Scholar
  6. Crow TJ (1980) Molecular pathology of schizophrenia: more than one disease process? Br Med J 280: 66–68.PubMedCrossRefGoogle Scholar
  7. Crow TJ (1985) The two-syndrome concept: origins and current status. Schizophr Bull 11: 471–486.PubMedGoogle Scholar
  8. Cutler NR, Jeste DV, Karoum F, Wyatt RJ (1982) Low-dose apomorphine reduces serum homovanillic acid concentrations in schizophrenic patients. Life Sci 30: 753–756.PubMedCrossRefGoogle Scholar
  9. Davidson M, Kendler KS, Davis BM, Horvath TB, Mohs RC, Davis KL (1985) Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients. Psychiatry Res 16: 95–99.PubMedCrossRefGoogle Scholar
  10. Ferrier IN, Johnstone EC, Crow TJ (1984) Clinical effects of apomorphine in schizophrenia. Br J Psychiatry 144: 341–348.PubMedCrossRefGoogle Scholar
  11. Gerbaldo H, Demisch L, Lehmann C-O, Bochnik J (1988) The effect of OPC-4392, a partial dopamine receptor agonist, on negative symptoms: results of an open study. Pharmacopsychiatry 21: 387–388.PubMedCrossRefGoogle Scholar
  12. Goldberg SC (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11: 453–456.PubMedGoogle Scholar
  13. Hollister LE, Davis KL, Berger PA (1980) Apomorphine in schizophrenia. Comm Psyehopharmacol 4: 277–281.Google Scholar
  14. Johnstone EC, Crow TJ, Frith CD, Husband J, Kreel L (1976) Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet II: 924–926.CrossRefGoogle Scholar
  15. Kammen DP van, Kammen WB van, Mann LS, Seppala T, Linnoila M (1986) Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Arch Gen Psychiatry 43: 978–983.PubMedCrossRefGoogle Scholar
  16. Levy MI, Davis BM, Mohs RC et al. (1984) Apomorphine and schizophrenia. Arch Gen Psychiatry 41: 520–524.PubMedCrossRefGoogle Scholar
  17. Mackay AVP (1980) Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 137: 379–383.PubMedCrossRefGoogle Scholar
  18. Meltzer HY (1980) Relevance of dopamine autoreceptors for psychiatry: preclinical and clinical studies. Schizophr Bull 6: 456–475.PubMedGoogle Scholar
  19. Meltzer HY, Sommers AA, Luchins DJ (1986) The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 6: 329–338.PubMedCrossRefGoogle Scholar
  20. Olbrich R, Schanz H (1988) The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenia. Pharmacopsychiatry 21: 389–390.PubMedCrossRefGoogle Scholar
  21. Roth RH, Wolf ME, Deutch AY (1987) Neurochemistry of midbrain dopamine systems. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 81–94.Google Scholar
  22. Seyfried CA, Greiner HE, Haase AF (1989) Biochemical and functional studies on EMD 49980: a potent, selectively presynaptic D-2 dopamine agonist with actions on serotonin systems. Eur J Pharmacol 160: 31–41.PubMedCrossRefGoogle Scholar
  23. Smith RC, Tamminga CA, Davis JA (1977) Effect of apomorphine on schizophrenic symptoms. J Neural Transm 40: 171–176.PubMedCrossRefGoogle Scholar
  24. Tamminga CA, Schaffer MH, Smith RC (1978) Schizophrenic symptoms improve with apomorphine. Science 200: 567–568.PubMedCrossRefGoogle Scholar
  25. Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44: 660–669.PubMedCrossRefGoogle Scholar
  26. Weinberger DR, Bigelow LB, Kleinman JE, Klein ST, Rosenblatt JE, Wyatt RJ (1980) Cerebral venticular enlargement in chronic schizophrenia: an association with poor response to treatment. Arch Gen Psychiatry 37: 11–13.PubMedCrossRefGoogle Scholar
  27. Wiedemann K, Benkert O, Holsboer F (1990) B-HT 920 — a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia. Pharmacopsychiatry 23: 50–55.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • H. Wetzel
  • A. Hillert
  • G. Gründer

There are no affiliations available

Personalised recommendations